Professor Porrello is the Theme Director of Stem Cell Biology and Head of the Heart Regeneration Group at the Murdoch Children’s Research Institute. He also directs the Melbourne Node of the recently established Novo Nordisk Foundation Centre for Stem Cell Medicine (reNEW) and he is the founding Co-Director of the Melbourne Centre for Cardiovascular Genomics and Regenerative Medicine (CardioRegen). Prof Porrello’s research focuses on the development of regenerative therapies for children and adults with heart failure. Over the course of his career, he has made important contributions to our understanding of mammalian heart regeneration and has pioneered the development of human organoids for drug discovery. Prof Porrello is a co-founder of Dynomics, a biotechnology company focused on the development of new heart failure treatments using organoid technologies.
After completing his PhD in Physiology at The University of Melbourne, Prof Porrello was awarded an NHMRC/NHF C.J. Martin Fellowship to undertake postdoctoral training in Prof Eric Olson's laboratory at UT Southwestern Medical Center in Dallas, USA. Upon returning to Australia in 2012, Prof Porrello established the Cardiac Regeneration Laboratory at The University of Queensland, which he co-headed together with Dr James Hudson from 2013-2017.
Professor Porrello is the Theme Director of Stem Cell Biology and Head of the Heart Regeneration Group at the Murdoch Children’s Research Institute. He also directs the Melbourne Node of the recently established Novo Nordisk Foundation Centre for...
Professor Porrello is the Theme Director of Stem Cell Biology and Head of the Heart Regeneration Group at the Murdoch Children’s Research Institute. He also directs the Melbourne Node of the recently established Novo Nordisk Foundation Centre for Stem Cell Medicine (reNEW) and he is the founding Co-Director of the Melbourne Centre for Cardiovascular Genomics and Regenerative Medicine (CardioRegen). Prof Porrello’s research focuses on the development of regenerative therapies for children and adults with heart failure. Over the course of his career, he has made important contributions to our understanding of mammalian heart regeneration and has pioneered the development of human organoids for drug discovery. Prof Porrello is a co-founder of Dynomics, a biotechnology company focused on the development of new heart failure treatments using organoid technologies.
After completing his PhD in Physiology at The University of Melbourne, Prof Porrello was awarded an NHMRC/NHF C.J. Martin Fellowship to undertake postdoctoral training in Prof Eric Olson's laboratory at UT Southwestern Medical Center in Dallas, USA. Upon returning to Australia in 2012, Prof Porrello established the Cardiac Regeneration Laboratory at The University of Queensland, which he co-headed together with Dr James Hudson from 2013-2017.
Top Publications
Mohenska, M, Tan, NM, Tokolyi, A, Furtado, MB, Costa, MW, Perry, AJ, Hatwell-Humble, J, van Duijvenboden, K, Nim, HT, Ji, YMM, et al.
3D-cardiomics: A spatial transcriptional atlas of the mammalian heart.
Journal of Molecular and Cellular Cardiology
163:
20 -32
2022
view publication
Voges, H, Parker, B, Quaife-Ryan, G, Friedmand, C, Palpant, N, Del Monte-Nieto, G, Elliott, D, Mills, R, Porrello, E, Hudson, J.
Development of a Vascularised Cardiac Organoid Platform Reveals a Regulatory Role for Extracellular Matrix Environment on Muscle Functionality.
Heart Lung and Circulation
31:
s310
2022
view publication
Wang, Z, Chan, H, Gambarotta, G, Smith, NJ, Purdue, BW, Pennisi, DJ, Porrello, ER, O'Brien, SL, Reichelt, ME, Thomas, WG, et al.
Stimulation of the four isoforms of receptor tyrosine kinase ErbB4, but not ErbB1, confers cardiomyocyte hypertrophy.
Journal of Cellular Physiology
236(12)
:
8160 -8170
2021
view publication
Redd, MA, Scheuer, SE, Saez, NJ, Yoshikawa, Y, Chiu, HS, Gao, L, Hicks, M, Villanueva, JE, Joshi, Y, Chow, CY, et al.
Therapeutic Inhibition of Acid-Sensing Ion Channel 1a Recovers Heart Function After Ischemia–Reperfusion Injury.
Circulation
144(12)
:
947 -960
2021
view publication
Lopes, LR, Garcia-Hernández, S, Lorenzini, M, Futema, M, Chumakova, O, Zateyshchikov, D, Isidoro-Garcia, M, Villacorta, E, Escobar-Lopez, L, Garcia-Pavia, P, et al.
Alpha-protein kinase 3 (ALPK3)-truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy.
European Heart Journal
42(32)
:
ehab424
2021
view publication